Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. In Canada, Biogen has been delivering life-changing medicines and services to Canadians affected by neurological conditions and rare disease for more than 25 years. Our team’s pioneering spirit and firm commitment to patients with complex diseases fuels our drive to innovate and help Canadians access ground-breaking treatments that can transform health, well-being and quality of life.